CompletedPhase 2NCT04703686
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The Lymphoma Academic Research Organisation
- Principal Investigator
- Guillaume Cartron, MD,PhDLymphoma Study Association
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (19)
- CHU Amiens Picardie Site sud, Amiens, France
- CHU de Clermont Ferrand, Clermont-Ferrand, France
- Hopital Henri Mondor, Créteil, France
- CHU de Dijon - Hôpital le Bocage, Dijon, France
- CHU de Grenoble, Grenoble, France
- CHRU Lille - Hôpital Claude Huriez, Lille, France
- CHU Montpellier, Montpellier, France
- CHU Nantes, Nantes, France
- Hôpital Saint Louis, Paris, France
- Hopital Necker enfants malades, Paris, France
- APHP - Hôpital de la Pitiè Salpetrière, Paris, France
- APHP - Hôpital Saint Antoine, Paris, France
- CHU de Bordeaux - Hôpital Haut Leveque, Pessac, France
- CHU Lyon Sud, Pierre-Bénite, France
- CHU de Rennes - Hôpital Pontchaillou, Rennes, France
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04703686 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah
- RECRUITINGPHASE2NCT07030699A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic